Zacks Investment Research
08 Jun 2026, 17:41 UTC · 2h ago
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Zacks Investment Research
08 Jun 2026, 17:41 UTC · 2h ago
Story key points
3 claims · impact-rated
The European Commission approved the subcutaneous formulation of Sanofi's multiple myeloma drug, Sarclisa. — Approval expands delivery options and patient convenience, likely supporting revenue growth and market share for the drug in the EU.
+0.40Sanofi is awaiting a final FDA decision next month regarding the US approval of the subcutaneous version of Sarclisa. — A positive US regulatory outcome would significantly expand the addressable market for this delivery method in a key region.
+0.30The subcutaneous version of Sarclisa reduces treatment administration time from several hours to approximately 13 minutes. — Increased efficiency for healthcare providers and patients creates a competitive advantage over the intravenous version.
+0.20Ticker attribution
Model heads
Continue reading
6 related stories
Top 2 movers · tap to explore
The European Commission approved the subcutaneous formulation of its drug Sarclisa, potentially increasing patient adoption and provider convenience.
Mentioned only as a partner/combinatory drug provider for the approved therapy.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Zacks Investment Research
3h ago
